{
    "organizations": [],
    "uuid": "3f7402b6508154d1ee43b2de776881c5ac530f2a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-achillion-announces-ach-4471-recei/brief-achillion-announces-ach-4471-receives-positive-opinion-for-orphan-drug-status-in-eu-for-the-treatment-of-c3-glomerulopathy-idUSFWN1QG0S8",
    "ord_in_thread": 0,
    "title": "BRIEF-Achillion Announces ACH-4471 Receives Positive Opinion For Orphan Drug Status In EU For The Treatment Of C3 Glomerulopathy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 26 (Reuters) - Achillion Pharmaceuticals Inc:\n* ACHILLION ANNOUNCES ACH-4471 RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR THE TREATMENT OF C3 GLOMERULOPATHY\n* ACHILLION - ‍EMA COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS ISSUED POSITIVE OPINION ON ACH-4471 FOR ORPHAN STATUS IN EU FOR C3 GLOMERULOPATHY​ TREATMENT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-26T19:31:00.000+02:00",
    "crawled": "2018-02-27T14:54:12.034+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "achillion",
        "pharmaceutical",
        "inc",
        "achillion",
        "announces",
        "receives",
        "positive",
        "opinion",
        "orphan",
        "drug",
        "designation",
        "european",
        "union",
        "treatment",
        "c3",
        "glomerulopathy",
        "achillion",
        "committee",
        "orphan",
        "medicinal",
        "product",
        "issued",
        "positive",
        "opinion",
        "orphan",
        "status",
        "eu",
        "c3",
        "treatment",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}